Jonathan W Wojtkowiak
Overview
Explore the profile of Jonathan W Wojtkowiak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1717
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pillai S, Mahmud I, Mahar R, Griffith C, Langsen M, Nguyen J, et al.
Cell Rep
. 2022 May;
39(6):110796.
PMID: 35545051
Malignant tumors exhibit altered metabolism resulting in a highly acidic extracellular microenvironment. Here, we show that cytoplasmic lipid droplet (LD) accumulation, indicative of a lipogenic phenotype, is a cellular adaption...
2.
McFarland C, Yaglom J, Wojtkowiak J, Scott J, Morse D, Sherman M, et al.
Cancer Res
. 2017 May;
77(18):4763-4772.
PMID: 28536279
Genomic instability and high mutation rates cause cancer to acquire numerous mutations and chromosomal alterations during its somatic evolution; most are termed passengers because they do not confer cancer phenotypes....
3.
Ibrahim-Hashim A, Robertson-Tessi M, Enriquez-Navas P, Damaghi M, Balagurunathan Y, Wojtkowiak J, et al.
Cancer Res
. 2017 Mar;
77(9):2242-2254.
PMID: 28249898
Ongoing intratumoral evolution is apparent in molecular variations among cancer cells from different regions of the same tumor, but genetic data alone provide little insight into environmental selection forces and...
4.
Zhang X, Wojtkowiak J, Martinez G, Cornnell H, Hart C, Baker A, et al.
PLoS One
. 2016 May;
11(5):e0155289.
PMID: 27227903
TH-302 is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. It is currently being evaluated in clinical trials, including two trials in...
5.
Sewda K, Coppola D, Enkemann S, Yue B, Kim J, Lopez A, et al.
Oncotarget
. 2016 Feb;
7(14):17773-89.
PMID: 26894861
Early detection of colorectal cancer (CRC) is crucial for effective treatment. Among CRC screening techniques, optical colonoscopy is widely considered the gold standard. However, it is a costly and invasive...
6.
Pilon-Thomas S, Kodumudi K, El-Kenawi A, Russell S, Weber A, Luddy K, et al.
Cancer Res
. 2016 Jan;
76(6):1381-90.
PMID: 26719539
Cancer immunotherapies, such as immune checkpoint blockade or adoptive T-cell transfer, can lead to durable responses in the clinic, but response rates remain low due to undefined suppression mechanisms. Solid...
7.
Damaghi M, Tafreshi N, Lloyd M, Sprung R, Estrella V, Wojtkowiak J, et al.
Nat Commun
. 2015 Dec;
6:8752.
PMID: 26658462
Early cancers are avascular and hence, profoundly acidic. Pre-malignant cells must adapt to acidosis to thrive in this hostile microenvironment. Here, we investigate MCF-7 cells that are adapted to grow...
8.
Enriquez-Navas P, Wojtkowiak J, Gatenby R
Cancer Res
. 2015 Nov;
75(22):4675-80.
PMID: 26527288
The dynamic cancer ecosystem, with its rich temporal and spatial diversity in environmental conditions and heritable cell phenotypes, is remarkably robust to therapeutic perturbations. Even when response to therapy is...
9.
Wojtkowiak J, Cornnell H, Matsumoto S, Saito K, Takakusagi Y, Dutta P, et al.
Cancer Metab
. 2015 Jan;
3(1):2.
PMID: 25635223
Background: Hypoxic niches in solid tumors harbor therapy-resistant cells. Hypoxia-activated prodrugs (HAPs) have been designed to overcome this resistance and, to date, have begun to show clinical efficacy. However, clinical...
10.
Bailey K, Cornnell H, Ibrahim-Hashim A, Wojtkowiak J, Hart C, Zhang X, et al.
PLoS One
. 2014 Dec;
9(12):e113586.
PMID: 25532146
Pancreatic ductal adenocarcinomas are desmoplastic and hypoxic, both of which are associated with poor prognosis. Hypoxia-activated prodrugs (HAPs) are specifically activated in hypoxic environments to release cytotoxic or cytostatic effectors....